Prognostic Value of PD-L1 in NSCLC
Launched by FONDAZIONE RICERCA TRASLAZIONALE · Mar 8, 2017
Trial Information
Current as of May 22, 2025
Unknown status
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Early stage treatment-naive NSCLC
- Exclusion Criteria:
- • Received any pre-surgical treatment
- • no OS data available
About Fondazione Ricerca Traslazionale
Fondazione Ricerca Traslazionale is a dedicated clinical research organization focused on advancing translational medicine to bridge the gap between laboratory discoveries and patient care. Committed to improving health outcomes, the foundation collaborates with academic institutions, healthcare providers, and industry partners to design and implement innovative clinical trials. By fostering a multidisciplinary approach, Fondazione Ricerca Traslazionale aims to accelerate the development of new therapies and enhance the understanding of disease mechanisms, ultimately contributing to the advancement of personalized medicine and improved therapeutic strategies.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials